NCT03392389

Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults

A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 124 (actual)
• Sponsor: ModernaTX, Inc. · Industry
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.

Conditions

• Human Metapneumovirus and Human Parainfluenza Infection

Interventions

Type	Name	Description
BIOLOGICAL	mRNA-1653	Escalating dose levels
OTHER	Placebo	Saline

Timeline

• Start date: 2017-12-04
• Primary completion: 2019-07-29
• Completion: 2019-07-29
• First posted: 2018-01-08
• Last updated: 2020-02-06

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study